Goldman Sachs downgrades Bicara Therapeutics stock rating to sell

Resumen del corpus

Goldman Sachs downgraded the stock rating for Bicara Therapeutics to 'Sell' from 'Neutral', setting a price target of $8.00. The downgrade was based on concerns regarding narrowing competitive prospects for the company's ficera in the head and neck cancer market, especially in light of positive Phase 3 results for Genmab's petosemtamab. The firm expressed low probability that ficera could compete effectively against petosemtamab and amivantamab in this competitive market.